Willingness to Pay for New Papanicolaou Test Technologies
| Autor: | Carey Andrew-JaJa, Dana Marie Grzybicki, Sharon C. Kiely, Alison R. Hart, Eugene Scioscia, Stephen S. Raab |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Financing
Personal medicine.medical_specialty Cost effectiveness Cost-Benefit Analysis Uterine Cervical Neoplasms Papanicolaou stain Reimbursement Mechanisms Willingness to pay Surveys and Questionnaires Humans Medicine Pap test Vaginal Smears Gynecology Cervical cancer medicine.diagnostic_test business.industry Health Care Costs General Medicine Papanicolaou Test medicine.disease Test (assessment) Patient Satisfaction Cytopathology Family medicine Income Female business Attitude to Health |
| Zdroj: | American Journal of Clinical Pathology. 117:524-533 |
| ISSN: | 1943-7722 0002-9173 |
| DOI: | 10.1309/xnug-xh8v-c1km-t6gd |
| Popis: | The amount of money a woman is willing to pay for liquid-based cytology technology has not been measured. In the present study, 175 women answered a questionnaire asking how much they would pay to decrease their risk of dying of cervical cancer if a new (liquid-based) Papanicolaou (Pap) test was used in place of the conventional smear. When women assumed that the new Pap test reduced the risk of dying of cervical cancer from 1 in 37,000 to 1 in 50,000, the mean amount they were willing to pay was $237. If women had more than 2 children, they were willing to pay more for the new Pap test than women with 2 or fewer children. These data indicate that liquid-based and conventional Pap tests are undervalued and that cost-effectiveness studies generally have not taken into account the preference of women for new Pap test technologies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|